Cell therapy is one of the most promising frontiers in medicine — but scaling it remains a massive challenge. In this episode, we explore the complex landscape of cell therapy manufacturing, where automation is both a critical solution and a major stumbling block. From high capital costs and regulatory hurdles to the lack of interoperable systems and specialized talent, we break down why so few companies have cracked the code.Then we look at how Cellistic is changing that. With its integrated Pulse™ and Echo™ platforms built on iPSC (Induced Pluripotent Stem Cell) technology, Cellistic is offering an end-to-end solution for "off-the-shelf" allogeneic therapies that’s faster, more reliable, and potentially game-changing. We discuss how automation not only cuts costs and reduces errors, but also supports scalability, quality control, and regulatory readiness — if done right.Whether you’re navigating your own manufacturing strategy or just trying to understand the future of scalable cell therapy, this episode is for you.🎙️ Topics Covered:Why automation is so hard to implement in cell therapyThe gap between automation’s promise and actual adoptionHow iPSCs unlock scalability for allogeneic therapiesWhat makes Cellistic’s Pulse™ and Echo™ platforms differentReal-world barriers (and enablers) of moving from benchtop to bedsideTune in to understand what’s standing in the way of cell therapy’s growth — and what’s finally pushing it forward.

Ver todos los episodios